CAS NO: | 290297-26-6 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Netupitant (formerly CID-6451149; AGE-94200; Ro 67-3189) is an orally bioavailable neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. It inhibits NK1 with a Ki of 0.95 nM. The combination drug netupitant/palonosetron was approved by FDA in 2018 for prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin. Netupitant competitively binds to and blocks the activity of the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in the prevention of chemotherapy-induced nausea and vomiting (CINV).
纯度:≥98%
CAS:290297-26-6